Abstract
Background: Immunotherapy has garnered attention in cancer treatment following the success of recent trials in solid tumors adopting PD-L1/PD-1 checkpoint inhibition. PD-1 is a T-cell checkpoint molecule that limits autoimmune and auto-inflammatory reactivity in the normal host by suppressing adaptive immune responses. Although PD-L1 expression in the tumor is generally considered a poor prognostic marker, it has been used to screen patients for cancer therapy since it is associated with a positive response to PD-L1/PD-1 blocking antibodies. Outline: This review focuses on the complex interconnections between cancer-reactive and selfreactive immune cells, as well as the potential contribution of a wide range of leading immunomodulatory chemical products from plant-based origins as cancer therapeutics or to foreseeably ameliorate autoimmune diseases. The natural compounds derived from plants should be used as a PD-L1/PD-1 checkpoint modulator to combat cancer cells and other chronic diseases. Conclusion: The significance of herbal plant extracts in the regulation of the PD-L1/PD-1 checkpoint is presented in this review together with the expression of PD-L1 and PD-1 in cancer cells and diseases in human bodies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
